

4. Priority is claimed under 35 U.S.C. 119/365 based on filing in _____ of _____ (country)

<u>Application No.</u>	<u>Filing Date</u>	<u>Application No.</u>	<u>Filing Date</u>
(1) _____	_____	(2) _____	_____
(3) _____	_____	(4) _____	_____
(5) _____	_____	(6) _____	_____

a. _____ (No.) Certified copy/copies attached.
 b. Certified copy/copies previously filed on _____ in
 U.S. Application No. _____ / _____, filed on _____
 series code ↑ ↑ serial no.
 c. Certified copy/copies filed during International stage of PCT/ _____ / _____.

4(a). (a) Domestic priority is claimed from PCT/ _____ / _____, filed _____.
 (b) Benefit is claimed of Provisional Application No. 60/_____, filed _____.

5. Assignee (optional) Georgetown University School of Medicine, Washington, DC

6. Attached is the following number of Assignments (including original and all later successive ones by different assignors): _____ and respective new Cover Sheets. (Do NOT file old cover sheets.)
 (Assignments in parent must be refiled with new Cover Sheets in this continuing application if you want it/them recorded against the continuing application.)

Please return the recorded Assignment to the undersigned.

The power of attorney in the prior application is to Robin L. Teskin, Registration No. 35,030

(Name and Reg. No.)
 whose current address is as in item 8 below.

a. Recognize as associate attorney _____

(Name, Reg. No. and Address)

8. **Address all future communications to Intellectual Property Group
 of Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102**

9. This application claims benefit of the following prior US application(s), the contents of which are incorporated into this application by this reference:

No. <u>09/ 354,109</u>	filed <u>July 15, 1999</u>
No. <u>08/ 957,327</u>	filed <u>October 24, 1997</u>
No. <u>/</u>	filed _____

No. PCT/ _____ / _____ filed _____, which
 designated the U.S. and that International Application was was not published under PCT Article 21(2) in English

9(a). See the attached Preliminary Amendment, which amends the first page of the specification to claim benefit of the above listed US application(s)

10. **Small Entity Status →** is Not claimed is claimed (pre-filing confirmation required)

1. (No.) Small Entity Statement(s) (not essential since 9/8/00) were/are:
 filed in above prior application
 attached.

11. Petition to extend the life of the above prior application to at least the date hereof
 (one box) is being concurrently filed in that prior application (Use Form PAT-111).
 (must be) was previously filed in that prior application (Check length of prior extension).
 (X'd) is not necessary for copendency (**Double check before X'ing this box**).

12. **INFORMATION DISCLOSURE STATEMENT:** Attached is Form PTO-1449 listing all of the documents cited by Applicant and the PTO in the parent application(s) relied upon under 35 USC 120 and referenced in item 9 above. Per Rule 98(d) copies of those documents are not required now. Please consider those documents and advise that they have been considered in this new application as by returning a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609. .

13. Attached is a Rule 103(a) Petition to Suspend Action.

14. Reserved

FILING FEE

THE FOLLOWING FILING FEE IS BASED ON

->->->CLAIMS AS FILED AND CHANGED BY PRELIMINARY AMENDMENT IN ITEM 14<-<-<-

NOTE: If box 1A2 is X'd, do not pay fees,
but leave lines 15-22 and 27-32 blank.

			Large/Small Entity	Fee Code
15. Basic Filing Fee	Design Application	\$320/\$160		106/26
16. Basic Filing Fee	Utility Application	\$710/\$355	+355	101/201
17. Total Effective Claims	minus 20 =	x \$18/\$9	+0	103/203
18. Independent Claims	minus 3 =	x \$80/\$40	+ 0	102/202
19. If any proper multiple dependent claim (ignore improper) is present,		\$270/\$135	+0	104/204
20.		Subtotal =	\$355	
21. If "petition" box 13 above is X'd, add petition fee.	\$130		+0	122
21A. If box 6 above is X'd, add Assignment recording fee	\$ 40		+0	581
22.	TOTAL FILING FEE ATTACHED =			\$355
	(carry forward to Item 31)			

23. ATTACHED: Unsigned Declaration by inventors (including one inventor added in the subject application).

24. See the attached Preliminary Amendment.

25. See NONPUBLICATION REQUEST under Rule 213(a) attached (Pat-258)

26.

**ADDITIONAL FEE CALCULATION FOR
PRELIMINARY AMENDMENT
PER BOXES 24/25**

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Additional Fee	
				Large/Small Entity	File Code
27.	Total Effective Claims <u>* 8</u>	minus ** <u>20</u>	= <u>0</u>	× \$18/\$9	= <u>\$ 0</u> (103/203)
28.	Independent Claims <u>* 1</u>	minus *** <u>3</u>	= <u>0</u>	× \$80/\$40	= <u>+ 0</u> (102/202)
29.	If amendment enters proper multiple dependent claim(s) into this application for the <u>first time</u> , add (per application)		\$270/\$135 <u>+ 0</u> (104/204)
30.				ADDITIONAL FEE	<u>\$ 0</u>
31.				plus <u>Fee</u> from item 22 on page 3	<u>+ 355</u>
32.				<u>TOTAL FEE</u>	<u>\$ 355</u>
33.	*If the entry in this space is less than a entry in the next space, the "Present Extra" result is "0"				
34.	**If the "Highest number previously paid for" (see item 17 above) is less than 20, write "20" in this space				
35.	If the "Highest number previously paid for" (see item 18 above) is less than 3, write "3" in this space				
	Deposit Account No. 03-3975 Our Order No. <u>082137</u>		0280652		
	C#		M#		



00909

CHARGE STATEMENT: Upon the filing of a Declaration pursuant to Rule 60(b) or 60(d), the Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

**Pillsbury Winthrop LLP
Intellectual Property Group**

By Atty: Robin L. Teskin Reg. No. 35,030

Sig: *R.L.T.* Fax: (703) 905-2500
Atty./Sec RLT/lak Tel: (703) 905-2200

NOTE No. 1: File this Request in duplicate with 2 postcard receipts (PAT-103) & attachments

NOTE No. 2: Is extension in parent necessary for copendency? DOUBLE CHECK Item 11 above.
If yes, printout Pat-111 and head it in parent.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re CONTINUATION
PATENT APPLICATION of

*

Usha KASID et al.

*

Group Art Unit: Unassigned

*

Application Serial No.: (Unassigned)

*

Examiner: Unassigned

*

Filed: August 16, 2001

*

Title: **LIPOSOMES CONTAINING OLIGONUCLEOTIDES**

* * * *

STATEMENT PURSUANT TO 37 C.F.R. §1.822

Hon. Commissioner of Patents
Washington, DC 20231

Sir:

Applicants hereby advise that this application contains the identical sequence disclosure as Serial No. 09/354,109, filed July 15, 1999 (the parent of this application (please note that this application was a divisional of U.S. Serial No. 08/957,327, filed October 24, 1997)). Accordingly, as paper and computer readable form of the Sequence Listing have been filed in said parent application, a duplicate need not be provided herein, pursuant to the provisions of 37 C.F.R. §1.1822(e). Applicants respectfully request that a computer readable form be generated corresponding to the sequence listing provided in the parent application.


J1000 U.S. PTO
09/930283
08/16/01



For the convenience of the Office, a copy of the Sequence Listing is provided herewith.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: August 1, 2001